Central and East European Oncology Group

  • Members
    Members

    CEEOG has greatly expanded and now includes 35 academic andcommunity hospitals from Poland, Romania, Slovakia, Bulgaria, Slovenia, Croatia, Bosnia and Hercegovina, Yugoslavia, Hungary, Czech Republic and Russia.

     

     

     

Polish Brain Metastasis Consortium

pbmc-logo

The group was founded in 2005 by Dr. Renata Duchnowska from the Military Medical Institute in Warsaw as a result of establishing an informal network of some Polish oncology centers. A year later group teamed up with foreign research groups and academic centers. In 2008, the patronage of the Group's research covered the CEEOG.

PathIES

Study team

Chief Investigator: Ewa Szutowicz-Zielińska, MD, PhD

Sponsor: CEEOG

Study Coordinator
Anna Gładysz, MSc.
GUMed

Study title

Intergroup Exemestane Study Pathology Sub-Study

Start date

01 September 2007

Study status

Closed

Background

The Intergroup Exemestane Study (IES) has shown improved disease free survival in postmenopausal women with early breast cancer who switched to the aromatase inhibitor (AI) exemestane, after 2-3 years of tamoxifen therapycompared to those who received tamoxifen alone for a total of five years of adjuvant therapy (Coombes et al., 2007). Despite the overall benefit demonstrated it is not yet possible to identify upfront which women would benefit from switching to exemestane.

PathIES is an academically led translational study that aims to address this question. It involves the retrospective collection of archived formalin fixed paraffin embedded (FFPE) blocks containing tissue from the primary tumour, recurrent tumour and contralateral breast carcinomas from women participating in the IES. Tumour tissue will be analysed for a set of biomarkers that have been shown to impact on sensitivity to AIs and/or tamoxifen.

By correlating the results of this analysis with patient outcome, we hope to identity those biomarkers that may be determinants of response to these treatment

CONTACT

Home
 
Medical University of Gdańsk
Department of Oncology and Radiotherapy
7 Dębinki Street
80-211 Gdańsk, Poland 
 
email
Phone: +48 58 349 2282
Fax: +48 58 349 22 44
E-mail: Ten adres pocztowy jest chroniony przed spamowaniem. Aby go zobaczyć, konieczne jest włączenie obsługi JavaScript.